Professor Liu Wen's team discovered the key regulatory mechanism of super enhancers in breast cancer and the corresponding targeted intervention...

Recently, the team of Professor Liu Wen of the State Key Laboratory of Cell Stress Biology, Fujian Provincial Key Laboratory of Drug New Target Research, and School of Pharmacy has discovered the epigenetic regulatory molecular mechanism
of estrogen receptor binding super-enhancers (ERa+) and the transcriptional activation of adjacent target genes in estrogen receptor-positive (ERa⁺) breast cancer cells 。 The study systematically identified estrogen receptor-bound super-enhancers in estrogen receptor-positive breast cancer; It was revealed that bromodomain-containing protein 4 (BRD4) was the key regulator of transcriptional activation of super-enhancers and their adjacent target genes, and the key adjacent target gene RET of super-enhancers was identified.

Estrogen receptor-positive breast cancer is the largest number of breast cancer subtypes, accounting for about 70% of the total number of breast cancers, endocrine therapy is commonly used first-line therapy, however, primary and acquired drug resistance is a key problem that needs to be urgently addressed in clinical practice
.

Previously, the research of Professor Liu Wen's team revealed that the protein complex formed by JMJD6 and BRD4 in members of the demethylase protein family containing jumonji C(jmjC) domain remotely regulates the activity of the P-TEFb protein complex by binding to genome-specific enhancers, thereby regulating the transcriptional regulation novel model of transcriptional extension of adjacent coding genes (Cell.

Professor Liu Wen and Dr.

Paper Link: https://academic.